Wells Fargo Downgrades Enzymotec (ENZY) to Market Perform

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. SPCX
2. LEVI
3. SBUX
4. NVDA
5. GOOGL
6. AAPL
7. SPY
8. APLD
9. ORCL
10. USO

Go back to Wells Fargo Downgrades Enzymotec (ENZY) to Market Perform

Enzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results

November 16, 2016 7:30 AM EST

Nutrition Segment increased Adjusted EBITDA* to $4M, representing 27% year-over-year and 17% sequential growth

VAYA Pharma sales to patients grew 45% year-over-year, but inventory destocking by wholesalers driven by the rapid adoption of VAYAs online pharmacy negatively impacts EPS by $0.05

MIGDAL HA'EMEQ, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the third quarter ended September 30, 2016.

Third Quarter 2016 Financial and Operational... More